Skip to main content
Premium Trial:

Request an Annual Quote

Verastem Taps LabCorp to Validate Companion Dx for Cancer Stem Cell Agent

NEW YORK (GenomeWeb News) – Verastem said today that Laboratory Corporation of America will help it validate biomarkers that could be used to develop a companion diagnostic for a Verastem drug candidate, the focal adhesion inhibitor VS-6063.

The biomarkers will be used in clinical studies in ovarian cancer and mesothelioma, including a potentially pivotal study of VS-6063 in mesothelioma expected to commence later this year.

Specifically, the partners will evaluate biomarkers related to the tumor suppressor Merlin. According to Verastem, around 50 percent of mesothelioma patients who lack Merlin may be responsive to treatment with FAK inhibitors.

VS-6063, which Verastem licensed from Pfizer last July, is designed to target and kill cancer stem cells by inhibiting FAK signaling.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.